Literature DB >> 15760142

Synthesis of pelorol and analogues: activators of the inositol 5-phosphatase SHIP.

Lu Yang1, David E Williams, Alice Mui, Christopher Ong, Gerald Krystal, Rob van Soest, Raymond J Andersen.   

Abstract

[reaction: see text] A screening program designed to find new antiinflammatory agents has identified the sponge meroterpenoid pelorol (1) as an in vitro activator of the inositol-5-phosphatase SHIP. Pelorol (1) and several functional group analogues have been synthesized from sclareolide (4).

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15760142     DOI： 10.1021/ol047316m

Source DB:  PubMed          Journal:  Org Lett        ISSN： 1523-7052            Impact factor:   6.005


  12 in total

1.  Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Jeffrey Kern; David Nethery; Balazs Halmos; Patrick Ma; Afshin Dowlati
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

2.  AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.

Authors:  Jennifer Cross; Grant R Stenton; Curtis Harwig; Csaba Szabo; Tiziana Genovese; Rosanna Di Paola; Emanuale Esposito; Salvatore Cuzzocrea; Lloyd F Mackenzie
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

3.  Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.

Authors:  Grant R Stenton; Lloyd F Mackenzie; Patrick Tam; Jennifer L Cross; Curtis Harwig; Jeffrey Raymond; Judy Toews; Joyce Wu; Nancy Ogden; Thomas MacRury; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

4.  Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.

Authors:  Elizabeth A Lemm; Beatriz Valle-Argos; Lindsay D Smith; Johanna Richter; Yohannes Gebreselassie; Matthew J Carter; Jana Karolova; Michael Svaton; Karel Helman; Nicola J Weston-Bell; Laura Karydis; Chris T Williamson; Georg Lenz; Jeremy Pettigrew; Curtis Harwig; Freda K Stevenson; Mark Cragg; Francesco Forconi; Andrew J Steele; Jennifer Cross; Lloyd Mackenzie; Pavel Klener; Graham Packham
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

Review 5.  Biologically active marine natural products and their molecular targets discovered using a chemical genetics approach.

Authors:  David E Williams; Raymond J Andersen
Journal:  Nat Prod Rep       Date:  2019-11-21       Impact factor: 13.423

Review 6.  Discovery and development of small molecule SHIP phosphatase modulators.

Authors:  William G Kerr; John D Chisholm; Dennis R Viernes; Lydia B Choi
Journal:  Med Res Rev       Date:  2013-12-02       Impact factor: 12.944

7.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

Review 8.  Dactylospongia elegans-A Promising Drug Source: Metabolites, Bioactivities, Biosynthesis, Synthesis, and Structural-Activity Relationship.

Authors:  Sabrin R M Ibrahim; Sana A Fadil; Haifa A Fadil; Rawan H Hareeri; Sultan O Alolayan; Hossam M Abdallah; Gamal A Mohamed
Journal:  Mar Drugs       Date:  2022-03-23       Impact factor: 6.085

Review 9.  Targeting SHIP1 and SHIP2 in Cancer.

Authors:  Chiara Pedicone; Shea T Meyer; John D Chisholm; William G Kerr
Journal:  Cancers (Basel)       Date:  2021-02-20       Impact factor: 6.639

10.  Synthesis of Pelorol and Its Analogs and Their Inhibitory Effects on Phosphatidylinositol 3-Kinase.

Authors:  Yongjie Luo; Huixuan Chen; Jiang Weng; Gui Lu
Journal:  Mar Drugs       Date:  2016-06-21       Impact factor: 5.118
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.